We represent a class of third-party payors who allege that the defendant abused the regulatory system by refusing to provide generic-drug manufacturers with samples of its blockbuster heart medication, Tracleer. This prevented the manufacturers from developing generic Tracleer, which allowed the defendant to continue selling the drug at inflated prices.